Results 261 to 270 of about 144,610 (311)

A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy. [PDF]

Breast
Valachis A, Liu X, Acs B, Hartman J, Foukakis T, Matikas A.   +5 more
europepmc   +1 more source

Total Neoadjuvant Therapy for Rectal Cancer: Why Japan Says "Not Yet". [PDF]

Ann Gastroenterol Surg
Uehara K, Matsuda A, Yamada T, Monkhonsupphawan A, Yoshida H.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Neoadjuvant Therapy for Breast Cancer

Annual Review of Medicine, 2015
Neoadjuvant treatment of breast cancer refers to the use of different treatment modalities prior to surgical excision of the tumor. It has been accepted as a treatment option for patients with nonmetastatic disease, because it renders inoperable tumors operable and increases the rates of breast-conserving surgery, while achieving similar long-term ...
Dimitrios Zardavas, Martine Piccart
exaly   +3 more sources

Neoadjuvant Therapy for Melanoma

Surgical Oncology Clinics of North America, 2020
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promising results with high pathologic response rates and acceptable safety.
Michael C, Lowe, Ragini R, Kudchadkar
openaire   +2 more sources

Neoadjuvant Therapy for Rectal Cancer

Surgical Oncology Clinics of North America, 2022
The treatment of locally advanced rectal cancer is challenging and requires a multidisciplinary approach. Neoadjuvant treatment has improved local control by the combination of radiotherapy, surgery, and chemotherapy. However, neoadjuvant treatment has not yet been shown to improve overall survival and is associated with toxicities and late sequelae ...
Felipe F, Quezada-Diaz, J Joshua, Smith
openaire   +2 more sources

Neoadjuvant therapy for pancreatic cancer

Nature Reviews Clinical Oncology, 2023
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic chemotherapy, which provides considerably longer overall survival (OS) durations than either modality alone. Regardless, most patients will have disease relapse owing to micrometastatic disease.
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, Philip A. Philip, Theodore S. Hong, Thilo Hackert, Markus W. Büchler, John Neoptolemos   +7 more
openaire   +2 more sources

The Role of Neoadjuvant Therapy in Melanoma

Current Oncology Reports, 2020
Neoadjuvant therapy in melanoma is an area of active investigation with numerous completed and ongoing trials studying a variety of therapeutic interventions utilizing diverse designs. Here, we review completed and ongoing neoadjuvant trials in melanoma, discuss endpoint assessment, and highlight biomarker development in this context.High-risk ...
Zahra R, Kelly, Vikram C, Gorantla, Diwakar, Davar   +2 more
openaire   +2 more sources